安伯瑞®
展商：Takeda Pharmaceutical Company Limited
原产国/地区：日本
安伯瑞® 是全新ALK酪氨酸激酶抑制剂（TKI），适用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性的非小细胞肺癌(NSCLC)患者的治疗。其二甲基氧化磷（DMPO）结构能够加强与ALK蛋白的结合力，增强药物活性，也为药物透过血脑屏障并保持脑部血药浓度创造有利条件，同时可广泛抑制多种ALK融合类型及耐药突变。
展品详情
Alunbrig is a new ALK TKI suitable for the treatment of non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positive. Its dimethyl phosphorus oxide (DMPO) structure strengthens the binding force with ALK protein, enhances the drug activity, and creates favorable conditions for the drug to pass through the blood-brain barrier and maintain the blood drug concentration in the brain. At the same time, it can widely inhibit a variety of ALK fusion types and drug resistance mutations.